{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:46:57Z","timestamp":1780462017823,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1124\/dmd.114.062828","type":"journal-article","created":{"date-parts":[[2015,5,2]],"date-time":"2015-05-02T01:03:11Z","timestamp":1430528591000},"page":"1077-1083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment"],"prefix":"10.1016","volume":"43","author":[{"given":"Robin","family":"O\u2019Connor-Semmes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth K.","family":"Hussey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurene","family":"Wang-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Dobbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bentley","family":"Cheatham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William O.","family":"Wilkison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.114.062828_bib1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/1756-0500-7-415","article-title":"Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging","volume":"7","author":"Bailey","year":"2014","journal-title":"BMC Res Notes"},{"key":"10.1124\/dmd.114.062828_bib2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2337\/diaclin.25.3.90","article-title":"Diabetes management issues for patients with chronic kidney disease","volume":"25","author":"Cavanaugh","year":"2007","journal-title":"Clin Diabetes"},{"key":"10.1124\/dmd.114.062828_bib3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition\u2014a novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.114.062828_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","article-title":"The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia","volume":"14","author":"DeFronzo","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/dmd.114.062828_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1463-1326.2011.01462.x","article-title":"Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients","volume":"14","author":"Dobbins","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/dmd.114.062828_bib6","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.2337\/dc12-1503","article-title":"Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes","volume":"36","author":"Ferrannini","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1124\/dmd.114.062828_bib7","unstructured":"Food and Drug Administration (2011) FDA Briefing Document. NDA 202293: Dapagliflozin tablets, 5 and 10 mg. Sponsor: Bristol-Myers Squibb. Endocrinoliogic and Metabolic Advisory Commitee Meeting. July 19, 2011."},{"key":"10.1124\/dmd.114.062828_bib8","unstructured":"Food and Drug Administration (2013) FDA Briefing Document. NDA 204042: Invokana (canagliflozin) Tablets. Applicant: Janssen Pharmaceuticals, Inc. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. January 10, 2013."},{"key":"10.1124\/dmd.114.062828_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/jpet.108.140210","article-title":"Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models","volume":"327","author":"Fujimori","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.114.062828_bib10","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/ndt\/gfn616","article-title":"Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?","volume":"24","author":"Haneda","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/dmd.114.062828_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/2050-6511-14-25","article-title":"Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus","volume":"14","author":"Hussey","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1124\/dmd.114.062828_bib12","first-page":"285","article-title":"Sodium-glucose cotransporter inhibitors for diabetes","volume":"8","author":"Isaji","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1124\/dmd.114.062828_bib13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116972","article-title":"The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose","volume":"93","author":"Kanai","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1124\/dmd.114.062828_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/2050-6511-14-26","article-title":"First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus","volume":"14","author":"Kapur","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1124\/dmd.114.062828_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/dom.12182","article-title":"Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment","volume":"16","author":"Macha","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/dmd.114.062828_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/bdd.1824","article-title":"Regional gastrointestinal delivery of remogliflozin etabonate in humans","volume":"34","author":"O\u2019Connor-Semmes","year":"2013","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.114.062828_bib17","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1124\/dmd.112.047258","article-title":"Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies","volume":"40","author":"Sigafoos","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062828_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.0894-0959.2004.17346.x","article-title":"Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease","volume":"17","author":"Snyder","year":"2004","journal-title":"Semin Dial"},{"key":"10.1124\/dmd.114.062828_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2005.05.010","article-title":"Effects of renal failure on drug transport and metabolism","volume":"109","author":"Sun","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.114.062828_bib20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/dom.12393","article-title":"Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes","volume":"17","author":"Sykes","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/dmd.114.062828_bib21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/dom.12391","article-title":"Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes","volume":"17","author":"Sykes","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/dmd.114.062828_bib22","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1681\/ASN.2005101085","article-title":"Chronic kidney disease and mortality risk: a systematic review","volume":"17","author":"Tonelli","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/dmd.114.062828_bib23","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1124\/dmd.114.062828_bib24","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metab"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624113098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624113098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.114.062828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:31:04Z","timestamp":1739907064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624113098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0090955624113098"],"URL":"https:\/\/doi.org\/10.1124\/dmd.114.062828","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.114.062828","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}